News 
Market Data 
Discover
JPetroInc
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
filled - hold em tight
INDEXR a.i.
after listening to the MONI Spaces X call again and again...
https://t.co/qFSgZoFdK2
IMHO only - I believe that OpenAI's ChatGBT & SearchGBT could potentially be working with INDEXR a.i. as a possible SEO partner, data provider, and/or trusted content disseminator. Below article is a good example of all the parts and pieces of affiliate companies which in-fill OpenAI's operating system backbone:
OpenAI: Our Approach to Data and AI
May 7, 2024
https://openai.com/index/approach-to-data-and-ai/
Duane Forrester specifically mentions OpenAI ChatGBT and OpenAI SearchGBT between MM 16:16 - 20:05, and provides a number of 'illustrations' under which INDEXR a.i. will be a solution in providing services that ChatGBT & GBTSearch will use. What is not mentioned after MM 20:05 is what those specific services of INDEXR a.i. will be.
DF @ MM 16:16
"Yeah, I'm going to expand a little bit on this one. We're seeing a lot happening all of a sudden - some key themes that are happening. You look at a company like OpenAI for example - they - I'm pretty sure everyone understands this, but for the sake of clarity I'll state it. They operate ChatGBT. They are on the cusp of announcing (I believe they already announced) VoiceGBT. There's a small subset of users for that new product. That should be out by the fall. They have announced SearchGBT which will be some version of search appendage to the SearchGBT that will um directly compete with Google, but in a new way. They believe that there is a common theme with consumers. That common theme is that consumers just want their answer, they want it quickly, they want to trust it, which means the data needs to be accurate and full. So they're (OpenAI) banking on a simplified interface where consumers don't have to scan, they don't have to go looking for things. You say what you want out loud, and you get that back. It checks a lot of boxes for humans. We are inherently lazy. It takes a lot of calories for us to think. So we are programed to essentially look for the easier path, which is why the concept of a 'hack' is very comfortable with humans - we're always looking for an easier way to accomplish a task. Having a voice system that is akin to asking a trusted friend to bring you back an answer is huge. How that answer comes back, and the trustworthiness of that is still all being worked out. Index's like ours (INDEXR a.i.) will help provide some of those answers, and ensure that all of the information is available. For a variety of reasons search engines may drop content, maybe due to size limitations. Even big companies like Microsoft and Google have limitations on the size of data they can hold in their servers. There are limits with that, and the amount of data that gets created every day is massive with us.
I will give you all a personal story that comes via a very close friend of mine to illustrate the changes that are coming. So, he went to his daughters school. He spoke in front of her class. There was a 'Bring Your Father to Work Day' that kind of thing, and this person happens to be a digital marketing consultant. So he went up in front of the class and started a Power Point presentation - as a marketing consultant would normally do - and starts to explain to an audience of 9 and 10 year old's that his job is to help businesses be successful by ranking highly in Google - and immediately a girl in the front row raises her hand and says to him "what's Google?" And there was some laughing and what not, and he looked at the teacher to confirm hat this wasn't a joke - and the teacher nodded to him - and it turns out the next thing the girl says is the most telling statement. She said, "I hear my parents talk about Google all the time, but I never go there." Now that child today - in 6 or 7 years - is going to be the consumer of tomorrow. And all they want are direct answers. They trust their influencers, they trust services and people they find in their areas like TicTok and InstaGram Reels, and in alternate search engines, because its quick and easy for them.
Uhm, I will wrap this up by saying it is highly doubtful any of us listen to our parents music. So change is coming. This (INDEXR a.i.) is going to be a part of that change and empowering business to remain successful."
How much money has Microsoft invested in OpenAI?
"In total, Microsoft's investment in OpenAI is reportedly worth as much as $13-Bil, albeit with mysterious and unorthodox terms. The ousting of OpenAI CEO Sam Altman highlighted a salient reality — that Microsoft's near - and long-term fate in the AI arms race lies squarely with OpenAI." - Dec 20, 2023
How much of ChatGPT is owned by Microsoft?
"No, Microsoft does not own ChatGPT. ChatGPT was developed by OpenAI, an independent artificial intelligence research organization. However, Microsoft has a partnership with OpenAI, and they collaborate on various projects." Dec 2, 2023
Did Microsoft buy 49% of OpenAI?
"Microsoft is entitled to up to 49% of the for-profit arm of OpenAI's profits, according to reports. But that's not the same as 49% ownership. That investment does not result in Microsoft owning part of OpenAI, which is now clearer following an update to the OpenAI website and clarification from the company." Dec 19, 2023
looking good Gerald...!
IMHO, you'll have this trading at $0.00028 in record time
here comes the Astoria Queens financial mafia wrecking crew to help assist you in your next financial debacle
so much for running TOMDF into insolvency and jumping ship to this firm which didn't last long:
Fortitude Advisors LLC
https://fortitudeadvisors.com/team/
"He is also the Chief Business Officer at OS Therapies, Inc. starting in 2024 and the Managing Partner at Fortitude Advisors LLC since 2019."
uh ho - Gerald Commissiong OSTX's new Chief Business Officer executive named...
and is the same old same old serial dilution 'scam artist' from AMBS & TOMDF
here we go again folks...!
buyers be ware - check these other 2 tickers for the catastrophic results by this Stanford Univ. Financial Engineering hack
https://ostherapies.com/leadership/
SMH - can't make this stuff up - sad but true...!
MOO tool
its obvious....
sounds like DB is looking for a hefty 'breach of contract' counter suit...!
some assisted INDEXR a.i networking...
Steven Marshall - INDEXR a.i. CEO & owner of Gibru
https://gibiru.com/
looking at Gibru's web-portal - you'll see a VPN tab atop the header
clicking on the VPN tab lands you here:
https://gibiru.com/vpn/#vpn
clicking through the "Try Ambit VPN now – 14 day free trial" lands you here:
https://www.ambitvpn.com/#/?ref=Gibiru-desktop
searching AmbitVPN lands you at American Binary:
https://www.ambit.inc/
scrolling down brings you to American Binary Partners here:
American Binary's Partner Shieldcom link lands you here:
https://shieldcoms.com/
Shieldcom also shows American Binary as its Partner here:
https://shieldcoms.com/partners-2/
Steven Marshall is a cofounder of Shieldcom
https://shieldcoms.com/about-2/
American Binary team members are a whose-who of x-US Military & US Intelligence Agency folks:
https://www.ambit.inc/team/
Sheildcom's subsidiary is NVIS - also a Shieldcom Partner
https://shieldcoms.com/partners-2/
https://nviscommunications.com/partners
SGW posted a wealth of info about Shieldcom here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174964037
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174964219
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174964300
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174964475
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174964584
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174964681
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174969545
NVIS mentions here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174980711
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174980620
BAF INDEXR.a.i.
sounds like a DB is looking for a hefty 'breach of contract' counter suit...!
Stepping Out of The Matrix says it all...
BAF INDEXR a.i.
I see what you're doing and....
I'm not going to take your bait and spar with you...!
but here is the "end result" of all your serial pumping, along with that of the TOMDF Back Office Boiler Room Pump Boys:
SMH - who knows, maybe a few pictures will help you to finally get the message...!
and if pictures don't help, here's some words that may...!
TOMDF Sham Exposed in 200 Chronological Order PR’s:
Todos Medical Announces Insolvency Proceedings in Israel
Dec 22, 2023 5:28pm EST
Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
Sep 26, 2023 11:01am EDT
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
Aug 30, 2023 8:19am EDT
Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics
Mar. 28, 2023
Todos Medical Begins Trading on the OTC Pink Marketplace
Mar. 27, 2023
Todos Medical Supports Long COVID Awareness Day
Mar. 15, 2023
Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders
Mar. 13, 2023
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics
Feb. 14, 2023
Todos Medical to Present at the RHK 2022 Disruptive Growth Conference
Dec. 06, 2022
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
Nov. 29, 2022
Todos Medical to Attend World Antiviral Congress
Nov. 22, 2022
Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
Nov. 16, 2022
Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A.
Nov. 10, 2022
Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA
Oct. 14, 2022
Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics
Oct. 06, 2022
Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform
Sep. 30, 2022
Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™
Sep. 27, 2022
Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd Hemp
Sep. 22, 2022
Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for #TolloUp Campaign
Sep. 16, 2022
Todos Medical Announces Preprint of Long COVID Case Study Participant with Confirmed Microclot and Hyperactivated Platelets who Benefitted from Tollovid
Sep. 15, 2022
Todos Medical & The Alchemist’s Kitchen to Host “Long COVID: An Integrated Approach” Event Benefitting Survivor Corps
Sep. 13, 2022
Todos Medical’s 3CL Protease Inhibitor Supplement Tollovid™ Featured in Wellness Magazine
Sep. 13, 2022
Todos Medical Partner NLC Pharma Assigns IP for Tollovir™, Tollovid™, and TolloTest™ into JV 3CL Pharma
Sep. 12, 2022
Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti
Sep. 09, 2022
Todos Medical Announce Kingcarlx as Brand Ambassador for the Tollovid #TolloUp Lifestyle Campaign
Sep. 02, 2022
Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production
Aug. 31, 2022
Todos Medical Expands COVID Onsite School Sample Collection to Include MonkeyPox Testing
Aug. 29, 2022
Todos Medical Announces Saliva-Only MonkeyPox Testing at CLIA/CAP Clinical Lab Provista Diagnostics
Aug. 26, 2022
Todos Medical Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series
Aug. 25, 2022
Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women
Aug. 23, 2022
Todos Medical Announces Commercialization of Lesion and Saliva-Based MonkeyPox PCR Testing
Aug. 22, 2022
Todos Medical Announces Preprint of Data from First 100 Participants in IRB-waived Market Research Study of Supplementation with Tollovid in Long COVID
Aug. 19, 2022
Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID
Aug. 15, 2022
Todos Medical Completes Trial Design for Tollovid™ Long COVID Clinical Study in Adults
Aug. 11, 2022
Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels at CLIA/CAP Lab Provista Diagnostics
Aug. 10, 2022
Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Aug. 08, 2022
Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics
Aug. 05, 2022
Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics
Aug. 03, 2022
Todos Medical Announces Preprint of Acute COVID-19 Paxlovid Rebound Rescued by Tollovid
Aug. 01, 2022
Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel
Jul. 28, 2022
Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid® Treatment Followed by Tollovid™ Dietary Supplementation
Jul. 22, 2022
Todos Medical Reports Case Study #7 in Acute and Long COVID
Jul. 12, 2022
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
Jun. 30, 2022
Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID
Jun. 23, 2022
Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff
Jun. 21, 2022
Todos Medical Completes Validation of 27 Pathogen UTI PCR Panel at Its CLIA/CAP Laboratory Provista Diagnostics
Jun. 13, 2022
Todos Medical Reports Day 45 Update for Case Study #6
Jun. 10, 2022
Todos Medical Reports Day 28 Update for Case Study #5 with Erectile Dysfunction
Jun. 07, 2022
Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET
Jun. 03, 2022
Todos Medical Reports Day 26 Update For Case Study #4
Jun. 01, 2022
Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference
May 27, 2022
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient
May 06, 2022
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
May 02, 2022
Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022
Apr. 27, 2022
Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics
Apr. 21, 2022
Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study
Apr. 20, 2022
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group
Apr. 19, 2022
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label
Apr. 06, 2022
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
Apr. 04, 2022
Todos Medical Reports Case Study of Patient with Long COVID
Mar. 31, 2022
Billy Blanks® Endorses Todos Medical’s Line of Tollovid® Products
Mar. 28, 2022
Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma
Mar. 16, 2022
Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs
Mar. 08, 2022
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
Jan. 27, 2022
Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Jan. 24, 2022
Pepperdine University Hosts the 22nd Annual Celebrity Flag Football Challenge®, Presented by Todos Medical’s Tollovid®
Jan. 19, 2022
Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies
Jan. 18, 2022
Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022
Jan. 12, 2022
Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022
Jan. 10, 2022
Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista
Dec. 27, 2021
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer’s Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing
Dec. 23, 2021
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
Dec. 22, 2021
Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing
Dec. 20, 2021
Todos Medical Announces “Test & Tollovid®” Holiday Package for Atlanta Area at Provista Diagnostics
Dec. 17, 2021
Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19
Dec. 16, 2021
Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes
Dec. 13, 2021
Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST
Dec. 10, 2021
Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics
Dec. 07, 2021
CEOs Presenting at the Emerging Growth Conference on December 8; Register Now
Dec. 07, 2021
Todos Medical to Present at Upcoming Emerging Growth Conference
Dec. 06, 2021
Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
Dec. 02, 2021
Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant
Nov. 30, 2021
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma
Nov. 29, 2021
Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece
Nov. 22, 2021
Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
Nov. 19, 2021
Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe
Nov. 18, 2021
Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test
Nov. 17, 2021
Todos Medical’s Provista Laboratory to Boost Top Line Through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests
Nov. 16, 2021
Todos Medical Reports Third Quarter 2021 Business and Financial Results
Nov. 15, 2021
Todos Medical Sees Significant Ramp Up in COVID PCR Testing Volume at Its Provista CLIA/CAP Lab with New Automation in Place
Nov. 02, 2021
Todos Medical Announces 2nd Clinical Trial Site for Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
Nov. 01, 2021
Todos Medical Announces Publication in Nature Neuroscience That Describes the Main Protease (3CL Protease) Causes Microvascular Brain Pathology
Oct. 25, 2021
Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection
Oct. 21, 2021
Todos Medical to Conduct Webinar Highlighting the cPass SARS-COV-2 Neutralizing Antibody Test for AMDA, The Society for Post-Acute and Long-Term Care Medicine, on October 22, 2021 at 12:00 PM EDT
Oct. 14, 2021
Todos Medical Announces Positive Data in Hospitalized and Outpatient Setting for TolloTest™, a Novel SARS-CoV-2 3CL Protease Biomarker Assay
Oct. 06, 2021
Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck
Oct. 04, 2021
Todos Medical Announces Positive Observational Trial Results for Oral Antiviral 3CL Protease (MPro) Inhibitor Tollovir®
Sep. 30, 2021
Todos Medical Receives Approval by Amazon to Sell Immune Supplements Tollovid® & Tollovid Daily™
Sep. 27, 2021
Todos Medical Reports Second Quarter 2021 Financial Results
Fri, Sep. 24, 2021
UPDATE: Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep. 24, 2021
Todos Medical Launches Tollovid Daily™ via Subscription at MyTollovid.com
Sep. 23, 2021
Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Oral Antiviral Drug Candidate Tollovir™
Sep. 20, 2021
Todos Medical Now Accepting Cryptocurrency for the Purchase of Tollovid® and Tollovid Daily™ Through Coinbase Commerce
Sep. 17, 2021
Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
Sep. 15, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of Combination COVID, Influenza A & B, RSV & hMPV Respiratory Panel Test
Sep. 01, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants
Aug. 26, 2021
Todos Medical’s CLIA/CAP Lab Provista Enters Into Reference Lab Agreement with Meadowlands Diagnostics to Provide cPass Neutralizing Antibody Blood Testing for Quantifying and Monitoring Key COVID-19 Immunity Biomarkers
Aug. 24, 2021
Todos Medical Completes Validation of cPass Neutralizing Antibody Blood Test at Provista Diagnostics to Quantify and Monitor Key Biomarkers of COVID-19 Immunity
Aug. 23, 2021
Todos Medical CEO to Appear on Fox Business Network Varney & Company Today at 11:40am to Discuss the Company’s Launch of cPass Neutralizing Antibody Testing for Monitoring COVID-19 Immunity
Aug. 23, 2021
Update: Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug. 05, 2021
Todos Medical Receipt Notice of Allowance from USPTO for 3CL Protease Inhibitor Dietary Supplement Tollovid™
Aug. 05, 2021
Todos Medical Makes Final Payment to Close Provista Diagnostics Acquisition
Aug. 02, 2021
Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir
Jul. 28, 2021
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Daily™ Including 3CL Protease Inhibitor Claim
Jul. 22, 2021
Todos Medical to Launch EUA Authorized cPass SARS-CoV-2 Neutralizing Antibody Kit Through Agreement with Fosun Pharma
Jul. 19, 2021
Todos Medical Appoints Ilanit Halperin, CPA as Corporate Controller
Jul. 07, 2021
Todos Medical Receives FDA Certificate of Free Sale for New 5-Day Tollovid Dosing Regimen
May 04, 2021
Todos Medical Launches Phase 2 Clinical Trial of Its Antiviral 3CL Protease Inhibitor NLC-V-01 (Tollovir) in Hospitalized COVID-19 Patients
Apr. 19, 2021
Todos Medical Receives Notice of Allowance from European Patent Office for Patent Application Covering Diagnosis of Cancer Using Proprietary Artificial Intelligence TBIA Immune Profiling Platform
Apr. 08, 2021
Todos Medical Completes Automation Equipment Installation and Training for Meadowlands Diagnostics
Apr. 01, 2021
Todos Medical Enters Into Distribution Partnership with Osang Healthcare for the GeneFinder Plus™ COVID-19 Plus RealAMP Kit in the United States
Mar. 30, 2021
Todos Medical Completes Automation Equipment Installation and Training for a Laboratory Client in Brooklyn, NY
Mar. 29, 2021
Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics
Mar. 23, 2021
Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021
Mar. 12, 2021
Todos Medical Applauds Senate and House Passage of the American Recovery Act
Mar. 11, 2021
Todos Medical Announces Strategic Investment by Yozma Group Korea
Jan. 25, 2021
Todos Medical Announces $4.8 Million in Sales for December 2020, a 50% Month Over Month Increase in Sales from November 2020
Jan. 11, 2021
Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of Kentucky
Dec. 23, 2020
Aditxt Signs Distribution Agreement with Todos Medical Ltd. For AditxtScore™ for COVID-19 Immune Monitoring Service
Dec. 14, 2020
Todos Medical Announces Commercial Launch of Proprietary 3CL Protease Inhibitor Dietary Supplement Tollovid™ at The Alchemist’s Kitchen
Dec. 07, 2020
Todos Medical Announces $3.2 Million in Sales for November 2020, a 269% Increase Sequential Month over Month Sales Growth from October 2020
Dec. 02, 2020
Todos Medical Provides Strategic Outlook
Dec. 01, 2020
Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR Testing
Nov. 24, 2020
Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action
Nov. 20, 2020
Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay
Nov. 18, 2020
Todos Medical Announces Clinical Validation and National CLIA Certification for MOTO+PARA Mobile High Complexity Labs
Nov. 17, 2020
Todos Medical Announces $867,000 in Sales for October 2020
Nov. 12, 2020
Todos Medical Trademarks Tollovid for Dietary Supplement NLC-001 and Enters Into Private Label & Distribution Agreement With The Alchemists Kitchen
Oct. 29, 2020
Todos Medical Announces Instrument Validation Complete at MOTO+PARA Mobile Lab
Oct. 26, 2020
Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep Point-of-Care Covid-19 Antibody Tests
Oct. 22, 2020
Todos Medical Receives Notices of Allowance From the European Patent Office Covering Use of TBIA Cancer Platform to Detect Benign Colon Cancer
Oct. 20, 2020
Todos Medical Reports $2.0 Million in Revenue for the Third Quarter of 2020
Oct. 13, 2020
Todos Medical Enters into Exclusive COVID-19 Testing Supply Agreement with MOTO+PARA’s National Mobile CLIA Lab Partner Integrated Health
Oct. 07, 2020
Todos Medical Enters into Exclusive Branding and Distribution Agreement with Melbourne Biotech for 96 and 384 Well RT-PCR Machines in the United States
Sep. 30, 2020
Todos Medical Enters Into COVID-19 PCR Testing Implementation and Equipment Financing Partnership with AID Genomics
Sep. 25, 2020
Todos Medical Expands Existing Contract for COVID-19 PCR Testing Equipment & Supplies with Wisconsin-based Laboratory to $47.5 Million
Sep. 22, 2020
Todos Medical CEO Releases Letter to Shareholders
Sep. 18, 2020
3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma
Sep. 17, 2020
Todos Medical Expands Partnership with Care G.B. Plus for Proprietary TBIA Cancer Tests to Include Europe, Israel and Africa
Sep. 16, 2020
Todos Medical Announces Commercial Launch of Todos Branded COVID-19 qPCR Test Kits in the United States
Sep. 11, 2020
Todos Medical Announces August Sales of $1,190,000, Up 100% Compared with July
Sep. 03, 2020
Todos Medical Enters Into Partnership With Pangea for COVID-19 Testing and Contact Tracing
Sep. 02, 2020
Todos Medical Announces $23,760,000 Contract for COVID-19 PCR Testing Equipment & Supplies With Wisconsin-based Laboratory
Aug. 31, 2020
Todos Medical to Present at The LD 500 Virtual Conference
Aug. 31, 2020
Todos Medical Announces $4,500,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
Aug. 27, 2020
Todos Medical Appoints Marsha Fontanive as VP of Sales and Chris Gross as VP of Sales Operations
Aug. 25, 2020
Todos Medical Announces $1.2 Million Contract for COVID-19 PCR Testing Equipment & Supplies with Texas-based Laboratory
Aug. 24, 2020
Todos Medical Announces $6,000,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory
Aug. 21, 2020
Todos Medical Announces Positive Proof-of-Concept Data for Novel 10-Minute Point-of-Care Saliva-based Test Detecting Active SARS-CoV-2 Infection
Aug. 17, 2020
Todos Medical Acquires Distribution Rights to SARS-CoV-2 Rapid Point-of-Care Antigen Test and Rapid Point-of-Care PCR Test
Aug. 14, 2020
Todos Medical Announces July Sales of COVID-19 Tests
Aug. 07, 2020
Todos Medical Announces Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
Aug. 06, 2020
Todos Medical Appoints Dr. Jorge Leon as Consulting Chief Medical and Scientific Officer of Infectious Disease and Oncology
Aug. 04, 2020
Pathnova Laboratories (PATHNOVA) Enters into Partnership to Commercialize Todos Medicals COVID-19 and Breast Cancer Tests in Singapore
Aug. 03, 2020
Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus
Jul. 28, 2020
Todos Medical Announces SARS-nCoV-19 Testing Kit Contract with NJ-Based Best Supply Clinical Laboratory
Jul. 27, 2020
Todos Medical Expands Management Team and Advisory Board
Jul. 20, 2020
Todos Medical Announces ANVISA Authorization in Brazil for 3D Med qPCR Kits and ANDis Extraction S
Jul. 16, 2020
Todos Medical Releases Letter to Shareholders
Feb 07, 2020 9:15am EST
Todos Medical Enters into Exclusive Option Agreement to Acquire Provista Diagnostics and Announces Management Changes
Jan 09, 2020 8:00am EST
Todos To Present At Upcoming 12th Annual LD Micro Main Event
Dec 06, 2019 7:29am EST
Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET
Nov 14, 2019 11:02am EST
Todos Medical to Present at Dawson James Small Cap Growth Conference
Oct 24, 2019 9:25am EDT
Todos Medical and Orot+ Announce First Patient Enrolled in Pre-Commercial Launch Preparations of TM-B1 and TM-B2 Breast Cancer Blood Screening Tests in Europe
Sep 24, 2019 9:14am EDT
Todos Medical Signs Binding Term Sheet with HWH World for Network Marketing of Blood Tests for the Early Detection of Breast Cancer
Sep 13, 2019 7:30am EDT
Todos Medical Enters into MOU to Expand Existing Early Detection Breast Cancer Blood Test Distribution Partnership with Orot+ into Japan
Sep 03, 2019 1:29pm EDT
Todos Medical Appoints Dr. Jorge Leon as Medical Advisor
Aug 06, 2019 7:00am EDT
Todos Medical Announces Positive Alzheimer's Biomarker Clinical Data from LymPro vs. Amyloid PET Interim Analysis
Jul 15, 2019 7:00am EDT
Todos Medical CEO Presented Corporate Update And Roadmap at The LD Micro Conference
Jun 17, 2019 8:30am EDT
Todos Medical Announces Positive Clinical Trial Data for Breast Cancer Blood Test TM-B1 in Dense Breasts
Jun 03, 2019 8:00am EDT
Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data
May 28, 2019 8:57am EDT
Todos Medical Receives Approval from Israeli Ministry of Health (AMAR) to Market and Sell its Breast Cancer Screens in Israel
May 23, 2019 8:00am EDT
Todos Medical Enters Exclusive Distribution Agreement with Care G.B. Plus, Ltd. for its Breast Cancer Screening Tests in Israel
May 21, 2019 8:00am EDT
Todos Medical Announces Voting Results from 2019 Annual Shareholder Meeting
May 03, 2019 8:52am EDT
Todos Medical Receives Notice of Allowance from the USPTO Covering the Early Diagnosis of Lung Cancer Using the Todos Biochemical Infrared Analysis (TBIA)
May 01, 2019 8:00am EDT
Todos Medical Enters Into Definitive Agreement With Orot+ for Exclusive Distribution Rights of its Breast Cancer Screening Tests in 2 European Countries
Apr 15, 2019 8:00am EDT
Todos and Amarantus Announce Completion of LymPro PET 1 Study by Leipzig University for Alzheimer’s Blood Diagnostic LymPro Test 2.0
Apr 08, 2019 7:30am EDT
Todos Medical to Present at Two Upcoming Investor Conferences
Mar 28, 2019 8:00am EDT
Todos Medical Appoints Dr. Colin Bier to Its Board of Directors
Mar 27, 2019 8:00am EDT
Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience
Feb 28, 2019 9:30am EST
Todos Medical Presents Encouraging Scientific Abstract at the San Antonio Breast Cancer Symposium (SABCS)
Dec 06, 2018 4:00pm EST
Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0
Dec 03, 2018 8:30am EST
Todos Medical to Present Scientific Abstract at the Upcoming San Antonio Breast Cancer Symposium (SABCS)
Nov 29, 2018 8:30am EST
Todos Medical, Ltd. Announces Additional Patent Issuance Covering the Use of IR Spectrum of Blood Plasma For Indicating the Presence of Breast Cancer
Oct 17, 2018 8:30am EDT
Todos Medical, Ltd. Signs Non-Binding Memorandum of Understanding with Orot+ for Distribution Rights of its Breast Cancer Screening Tests in Romania and Austria
Sep 13, 2018 8:30am EDT
Todos Medical, Ltd. Appoints Herman Weiss, MD MBA as New Chief Executive Officer
Jul 31, 2018 4:03pm EDT
Todos Medical reports on results of clinical trials for its blood test for breast cancer screening (TM - B1) conducted at Kaplan Hospital in Rehovot, Israel
Mar 22, 2018 8:00am EDT
Todos Medical initiates clinical trial of its blood test for breast cancer in Kaplan Hospital, Rehovot, Israel for subjects undergoing breast cancer screening
Mar 05, 2018 8:00am EST
U.S. Patent and Trademark Office has granted to Todos Medical two additional patents
Feb 12, 2018 8:00am EST
Mr. David Ben Naim, CPA, MBA Joins Todos Medical as Chief Financial Officer
Feb 06, 2018 8:00am EST
Todos Medical Appoints Dr. Meir Silver as Vice President of Clinical Research and Regulatory Affairs
Aug 29, 2017 8:30am EDT
MOO dung
would be simply 'outstanding'...
"if" this were trading $0.10 pps and above on news...
INDEXR a.i. "ANTICIPATED REGULATIONS"
sorry thewordsman - but how you think and how you feel is exactly that
those are your thoughts, your feelings, your reactive actions, and responsibilities
unfortunately you do not know or understand what I do - having been involved since 2012 - and you never will - so be thankful you never have to go thru what I did with this individual
hopefully the end result of my 'freedom of speech' has resulted in at least some TOMDF and AMBS shareholders not loosing some or all of their money...!
to what I consider to be a serial public security scammer, liar, manipulator, and user - who has not unequivocally destroyed 1 - but now 2 public securities
this sites' public security (TOMDF) was declared insolvent and dissolved long ago - having gone thru $138-Mil. and 200 completely worthless PR's, all of which amounted to absolutely nothing in less than 5 years time - excpet for t lining the pockets of these unscrupulous and nefarious culpable scam artists
the salaries these corp. officers were taking down were some the largest in the history of the OTC
if you do not have the mental acuity to "cop-a-clue" after all this time, and "comprehend" what exactly happened - to not only TOMDF but AMBS shareholders as well, then that is on you and you alone sir...!
but here is and will continue remaining my mission - to protect the innocent, naïve, speculative, under-informed, and prospective shareholders from repeating what I did, by trusting a scam artist, and a serial one at that...!
WARNING: to all prospective OSTX shareholders, this guy is on his 3 public security - just like he said he would do...!
SMH - you simply can't make this stuff up folks...!
MOO stunad
may be past history of equity distribution
https://ih.advfn.com/stock-market/USOTC/moon-equity-pk-MONI/trades
sucking-up that float
also the "DB-He-Man-Crush" - what's up with his shares...?
absolutely no worries here - I know what I own - still accumulating ...!
$MONI
Steven Marshall - Google Search Resident Expert
sitting on the next post Google Anti-Trust law suit a.i. open-web search engine called INDEXR a.i.
which may be running PQE and/or QKD data encryption operating system software
wouldn't want not having MONI shares in hand ...
when the Google Search Engine monopoly music stops...!
$MONI - Bullish as Fok...
MOO
he'll bring his Astoria, Queens financial mafia into OSTX
and destroy this new public security with toxic death spiral financing...
https://ir.ostherapies.com/
Common Stock par value $0.001, 50,000,000 shares authorized, 5,991,041 and 5,340,000 issued and outstanding, respectivel
Preferred Stock, par value $0.001, 5,000,000 shares authorized, 0 and 1,302,082 shares Preferred Stock A issued and outstanding
Accumulated deficit: (32,565,900)
Total Stockholders’ Deficit: (27,063,937)
love the 20 year old photo
SMH - wash rinse repeat...!
MOO dolt
best to fact-check whose who...!
https://www.otcmarkets.com/stock/MONI/profile
MONI
you know what Maria - one does not necessarily "have to have" their own photo as a backdrop to their Linked-In profile...
https://www.linkedin.com/in/richard-rich-lepoutre-861613/
in order to be thanked for their dedicated service to this great nations of ours - now do they - you tell me sir...!
but this backdrop is not in Richard Lepoutre's Linked-In profile either:
https://causeaction.com/2019/04/19/richs-vids-causeaction-goes-to-afghanistan-did-that/
nor is this one - which shows Richard Lepoutre out of uniform...
and as a civilian in Afghanistan - when the war was still active, hot, and utterly raging out of control
CauseACTION Goes To Afghanistan. Did That.
Posted by Rich Lepoutre | Apr 19, 2019
https://www.google.com/search?q=richard+lepoutre%2C+military+background&rlz=1C1FLDB_enUS738US738&sourceid=chrome&ie=UTF-8#vhid=YE6qY1hzsrsh5M&vssid=_hebmZtPBOrmviLMPgZWugAg_79
CauseAction was Rich Lepoutre's, among a host of other charitable NPO's and global efforts, causes and organizations
it's not about the messenger - its about the message - and it's about the things they dedicate their 'life' to and what they accomplished in putting themselves in harms way - to bring about positive, meaningful and loving 'change' that matters Maria...!
and IMHO, this old world is so desperate for more people like Rich Lepoutre ..!
Richard (Rich) Lepoutre was a "humanitarian" who loved people - and was involved in bettering humanity wherever and whatever he did...!
if one has to be schooled about what being a selfless humanitarian is at this stage in their life...
versus being a chorionic negative, self serving, self absorbed, egocentric, condescending, and miserable human being
then I am truly sorry for that person - and I pray they get help in order to have a better life going forward...
SMH - simply unbelievable - can't make this stuff up folks...!
Bullish as Fok - INDEXR a.i.
MOO
just WoW developments
Rich Lepoutre's passing appears to be a fast occurrence, given his inability to attend the MONI Spaces X conference call
ever think that just "maybe" this is the reason why they didn't take Q&A's
I'm sure Steven Marshall has been double and maybe triple taxed with not only his, but Rich's responsibilities as well, these past 3 months on the MONI acquisition
I'm almost certain that JL and FO had also been working doublet-timed - given the constraints this matter posed on the acquisition closing and its timeliness
all said, many thanks to Rich Lepoutre for his tireless service to the freedoms, liberties, privilege's and preservation of this great nations unwavering democratic principles, values, and the American way of life
RIP Rich Lepoutre
pragmatic post - well written - well stated
and no BS...!
TY - $MONI
AI
